What’s Happening in the RRP Community
What’s Happening in the RRP Community
Stay informed on the latest developments in RRP research, treatment advances, clinical trial opportunities, and advocacy efforts. This is your source for news that matters to patients, caregivers, and clinicians navigating the evolving landscape of recurrent respiratory papillomatosis care.
BackTable ENT Podcast Discusses Immunotherapy for Adults with RRP
Dr. Aaron Friedman joins the BackTable ENT podcast to discuss immune-directed therapy for RRP, including the FDA-approved PAPZIMEOS vaccine and what clinical trial data reveal about durable treatment responses in adults.
Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP
RRPF has published a new position statement outlining an evidence-based management algorithm for adults with RRP, developed by key opinion leaders with direct patient input.
Update on INO-3017 FDA Review and RRPF Advocacy
INOVIO's Biologics License Application for INO-3017 has been accepted by the FDA. RRPF shares an update on the review process and our advocacy for the accelerated approval pathway.
FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
INOVIO announced that the FDA has accepted its Biologics License Application for INO-3107 for review as a potential treatment for adults with RRP. Here's what this milestone means for our community.
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
INOVIO announced it has completed the rolling submission of its Biologics License Application for INO-3107. RRPF President Kim McClellan shares what this milestone means for our community.